Fab’entech, a French biotech specialised in the development and production of polyclonal antibodies, presents its new industrial site located in Saint-Priest, to the south-east of Lyon. The 1,000 m2 production site is now operational and will give Fab’entech the capacity to manufacture all of its innovations (biodefense and anti-COVID-19 programme: FabenCOV®) in France. Close-up of this new site, a key asset in the development of the biotech’s activities.
Sébastien Iva is the new Chief Executive Officer of Fab’entech, a Lyon-based biotech created in 2009 and specialised in the development and production of polyclonal antibodies intended for the treatment of emerging infectious diseases and the development of biodefense solutions. His mission is to ensure its development and transformation, with the stated objective of becoming a key player in the field of polyclonal antibodies. He took over from Bertrand Lépine, founder of Fab’entech, who now becomes a member of the Supervisory Council.
Lyon, dated 31 January 2020: Fab’entech, a Lyon-based biopharmaceutical company created in 2009 and specialised in immunotherapy for emergency situations, completes a new round of fundraising of 8.5 million euros led by Definvest, the fund of the Armed forces ministry managed by Bpifrance, with the participation of the Institut Mérieux and of its historical investors, …